We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

104 hedge funds and large institutions have $1.41B invested in Ventyx Biosciences in 2022 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 29 increasing their positions, 20 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,367% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 3

245% more capital invested

Capital invested by funds: $408M → $1.41B (+$1B)

65% more funds holding

Funds holding: 63104 (+41)

50% more funds holding in top 10

Funds holding in top 10: 46 (+2)

45% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 20

11.64% more ownership

Funds ownership: 68.1%79.74% (+12%)

12% less call options, than puts

Call options by funds: $1.97M | Put options by funds: $2.25M

Holders
104
Holders Change
+41
Holders Change %
+65.08%
% of All Funds
1.79%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.1%
New
44
Increased
29
Reduced
20
Closed
3
Calls
$1.97M
Puts
$2.25M
Net Calls
-$277K
Net Calls Change
-$277K
Name Holding Trade Value Shares
Change
Change in
Stake
PNC Financial Services Group
101
PNC Financial Services Group
Pennsylvania
$2K -$3.14K -142 -73%
QCG
102
Quadrant Capital Group
Ohio
$2K
Carson Wealth (CWM LLC)
103
Carson Wealth (CWM LLC)
Nebraska
$1K
Point72 Asset Management
104
Point72 Asset Management
Connecticut
-$2.52M -206,400 Closed
UBS Group
105
UBS Group
Switzerland
-$25K -2,052 Closed
Nisa Investment Advisors
106
Nisa Investment Advisors
Missouri
+$399 +18 New

VTYX Hedge Fund Activity: Q3 2022 in Review

104 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q3 2022, worth a combined $1.41B — up 245% from $408M a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new VTYX positions and 3 closed out — a net gain of 41 holders — while 29 added to existing stakes and 20 trimmed.

The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $38.5M. The largest seller was OrbiMed, cutting an estimated $23.6M.

  • 104 institutional investors held Ventyx Biosciences (VTYX) as of Q3 2022, up from 63 in Q2 2022.
  • Funds reported $1.41B of Ventyx Biosciences stock for Q3 2022, up 245% quarter-over-quarter.
  • 44 funds opened new Ventyx Biosciences positions in Q3 2022 and 3 closed out, a net change of +41 holders.
  • The largest Ventyx Biosciences buyer in Q3 2022 was Lord, Abbett & Co, an estimated $38.5M added.
  • The largest Ventyx Biosciences seller in Q3 2022 was OrbiMed, an estimated $23.6M sold.

Based on aggregated 13F filings for Q3 2022.